SCHEMBL930160

SCHEMBL930160

CCOC(=O)c1cc(C)c(Cl)nc1Nc1ccc(I)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.59
NPSR1 Q6W5P4 4/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RAB9A P51151 2/20 0.44
XBP1 P17861 1/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 1/20 0.44
HSD17B10 Q99714 1/20 0.44
MAPT P10636 5/20 0.43
LMNA P02545 2/20 0.43
THRB P10828 1/20 0.43
SLC2A1 P11166 1/20 0.43
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
DHODH Q02127 2/20 0.42
NPC1 O15118 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL929841 0.88 MAPT (0.51) SYKNPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL930913 0.83 MAP2K1 (0.55) SYKMAPTTHRBTDP1
SCHEMBL928951 0.77 SMN1; SMN2 (0.47) NPSR1MEN1KMT2ASMN1; SMN2RAB9A
SCHEMBL20560379 0.74 CASP1 (0.54) SMN1; SMN2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1353552 0.74 SYK (1.00) SYKNPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL929220 0.72 MAP2K1 (0.43)
SCHEMBL8656659 0.72 GLP1R (0.46) NPSR1KMT2AXBP1KDM4EALDH1A1
SCHEMBL12943698 0.72 MEN1 (0.38) SYKMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL4713013 0.71 SYK (0.67) SYKNPSR1MEN1KMT2ASMN1; SMN2
SCHEMBL609694 0.70 CASP1 (0.43) SMN1; SMN2KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015392-A1 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 ASTRAZENECA AB 2011-01-20 US disclosed
US-20110015392-A1 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 ASTRAZENECA AB 2011-01-20 US disclosed
EP-2252588-A2 PROCESS FOR PREPARING PYRIDONE DERIVATIVES AstraZeneca AB (SE) 2010-11-24 EP disclosed
WO-2009101432-A2 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 ASTRAZENECA AB (SE) 2009-08-20 WO disclosed
WO-2009101432-A2 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 ASTRAZENECA AB (SE) 2009-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015392-A1 PROCESS FOR PREPARING PYRIDONE DERIVATIVES 226 PDXK, MAPK1, PNPO SYK 668/4885NPSR1 3102/4885MEN1 529/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.